Skip to main content
Contact Us
Subscribe
E-Edition
52°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Entertainment
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cymabay Therapeutics
(NQ:
CBAY
)
8.470
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 24, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
8.470
Bid (Size)
4.100 (1)
Ask (Size)
8.980 (1)
Prev. Close
8.470
Today's Range
8.470 - 8.470
52wk Range
1.670 - 10.05
Shares Outstanding
84,677,939
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Preview: CymaBay Therapeutics's Earnings
March 15, 2023
Via
Benzinga
Analyst Expectations for CymaBay Therapeutics's Future
March 07, 2023
Via
Benzinga
Performance
YTD
+42.11%
+42.11%
1 Month
+5.35%
+5.35%
3 Month
+53.44%
+53.44%
6 Month
+144.80%
+144.80%
1 Year
+168.89%
+168.89%
More News
Read More
Analyst Expectations for CymaBay Therapeutics's Future
February 08, 2023
Via
Benzinga
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 24, 2023
Via
Benzinga
Why CymaBay Therapeutics Shares Are Rising
January 24, 2023
Via
Benzinga
CymaBay's New Seladelpar Two-Year Data Shows Improved Transplant-Free Survival
May 23, 2022
Via
Benzinga
CymaBay Therapeutics: Q1 Earnings Insights
May 12, 2022
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
January 23, 2023
Via
Benzinga
5 Most Expensive Health Care Stocks You Should Worry About
January 03, 2023
Via
Benzinga
CymaBay Therapeutics: Q2 Earnings Insights
August 11, 2022
Via
Benzinga
Earnings Outlook For CymaBay Therapeutics
August 10, 2022
Via
Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
August 01, 2022
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 27, 2022
Via
Benzinga
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
June 23, 2022
Via
Benzinga
79 Biggest Movers From Yesterday
June 08, 2022
Via
Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
June 07, 2022
Via
Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
May 22, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
May 18, 2022
Via
Benzinga
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
May 12, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
April 22, 2022
Via
Benzinga
The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill
March 18, 2022
Via
Benzinga
CymaBay Therapeutics: Q4 Earnings Insights
March 17, 2022
Via
Benzinga
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
March 17, 2022
Via
Benzinga
Earnings Scheduled For March 17, 2022
March 17, 2022
Via
Benzinga
A Preview Of CymaBay Therapeutics's Earnings
March 16, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.